Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats

J Microencapsul. Jul-Aug 2000;17(4):405-11. doi: 10.1080/026520400405660.

Abstract

An oral formulation based on liposome encapsulated alginate-chitosan gel capsules was developed for insulin delivery for the treatment of diabetes. Liposome encapsulation helped to increase the encapsulation efficiency of insulin in alginate-chitosan capsules. This formulation delivers insulin in the neutral environment of the intestine, by-passing the acidic media in the stomach, with increased drug absorption and bioavailability. Oral administration of this formulation was found to reduce blood glucose levels when tested in diabetic rats.

MeSH terms

  • Administration, Oral
  • Alginates / administration & dosage
  • Animals
  • Biological Availability
  • Blood Glucose / metabolism
  • Capsules
  • Chitin / administration & dosage
  • Chitin / analogs & derivatives
  • Chitosan
  • Delayed-Action Preparations
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / metabolism
  • Drug Compounding
  • Glucuronic Acid
  • Hexuronic Acids
  • In Vitro Techniques
  • Insulin / administration & dosage*
  • Insulin / pharmacokinetics
  • Intestinal Absorption
  • Liposomes
  • Male
  • Rats

Substances

  • Alginates
  • Blood Glucose
  • Capsules
  • Delayed-Action Preparations
  • Hexuronic Acids
  • Insulin
  • Liposomes
  • Chitin
  • Glucuronic Acid
  • Chitosan